sorafenib has been researched along with Hypertrophy, Right Ventricular in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hikasa, Y; Leong, ZP | 1 |
| Desai, AA; Garcia, JG; Gomberg-Maitland, M; Husain, AN; Lang, RM; Liu, Y; Lussier, YA; Maitland, ML; Moreno-Vinasco, L; Ratain, MJ; Sam, L; Sammani, S; Singleton, PA | 1 |
2 other study(ies) available for sorafenib and Hypertrophy, Right Ventricular
| Article | Year |
|---|---|
Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Autophagy; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Indoles; Male; Monocrotaline; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pulmonary Artery; Pyrroles; Rats, Wistar; Signal Transduction; Sorafenib; Vascular Remodeling; Ventricular Function, Right; Ventricular Remodeling | 2018 |
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.
Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Proliferation; Complement C1q; Disease Models, Animal; Enzyme Activation; Gene Expression Profiling; Genomics; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; Mitogen-Activated Protein Kinases; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Inbred Dahl; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Transforming Growth Factor beta3; Vascular Endothelial Growth Factor Receptor-2 | 2008 |